|
|
T24
|
|
|
C O'Toole
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: urinary bladder
Disease: transitional cell carcinoma
|
|
|
tumor specific antigen
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
transfection host (Roche FuGENE® Transfection Reagents
technology from amaxa)
|
|
|
Yes
|
|
|
HLA A1, A3, B18, Bw35, Cw4, DRw2, Dw4
|
|
|
Amelogenin: X
CSF1PO: 10,12
D13S317: 12
D16S539: 9
D5S818: 10,12
D7S820: 10,11
THO1: 6
TPOX: 8,11
vWA: 17
|
|
|
hypodiploidy to hypopentaploidy; stemline 86; 2 to 4 telocentrics; 3 to 4 minutes, hypotetraploid to hypertetraploid with abnormalities including dicentrics, breaks, pulverization, minutes and telocentric markers
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
|
Culture medium, 95%; DMSO, 5%
|
|
|
recommended serum:ATCC 30-2020
|
|
|
21849: O'Toole CHuman bladder cancer lines: HLA Class I and Class II antigen expression and susceptibility to cytostatic and cytotoxic effects in vitroIn: O'Toole CIn vitro models for cancer researchvol. IVBoca Raton, FLCRC Presspp. 103-125.
22365: O'Toole C, et al. Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy. Int. J. Cancer 10: 77-91, 1972. PubMed: 4196436
22443: Williams BY, Schonbrunn A. Bombesin receptors in a human duodenal tumor cell line: binding properties and function. Cancer Res. 54: 818-824, 1994. PubMed: 8306345
22510: Bubenik J, et al. Cellular and humoral immune responses to human urinary bladder carcinomas. Int. J. Cancer 5: 310-319, 1970. PubMed: 5452065
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
22849: Bubenik J, et al. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int. J. Cancer 11: 765-773, 1973. PubMed: 4133950
23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212
23256: Carey TE, et al. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA 73: 3278-3282, 1976. PubMed: 1067619
24381: Fogh J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl. Cancer Inst. Monogr. 49: 5-9, 1978. PubMed: 571047
25065: Bellet D, et al. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res. 57: 516-523, 1997. PubMed: 9012484
26316: Bubenik J, et al. Cellular immunity to renal carcinomas in man. Int. J. Cancer 8: 503-513, 1971. PubMed: 5137312
32266: Bender CM, et al. Inhibition of DNA methylation by 5-Aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58: 95-101, 1998. PubMed: 9426064
33025: Ponton A, et al. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J. Biol. Chem. 271: 8991-8995, 1996. PubMed: 8621545
|
|
